Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick M Brunner

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Experimental Dermatology|June 16, 2016
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitisSaakshi Khattri, Patrick M Brunner, Sandra Garcet, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
The Journal of Allergy and Clinical Immunology|September 28, 2016
Early-onset pediatric atopic dermatitis is T<sub>H</sub>2 but also T<sub>H</sub>17 polarized in skinHitokazu Esaki, Patrick M Brunner, Yael Renert-Yuval, et al.
Allergo Journal : Interdisziplinare Zeitschrift Fur Allergologie Und Umweltmedizin : Organ Der Deutschen Gesellschaft Fur Allergie- Und Immunitatsforschung|August 16, 2021
Eva Untersmayr, Elisabeth Förster-Waldl, Michael Bonelli, et al.
The Journal of Allergy and Clinical Immunology|August 20, 2018
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabPatrick M Brunner, Ana B Pavel, Saakshi Khattri, et al.
Allergo Journal International|June 28, 2021
Immunologically relevant aspects of the new COVID-19 vaccines-an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paperEva Untersmayr, Elisabeth Förster-Waldl, Michael Bonelli, et al.
The New England Journal of Medicine|August 20, 2025
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell TherapyAdolfo Aleman, Oliver Van Oekelen, David T Melnekoff, et al.
Nature Immunology|December 2, 2024
Author Correction: Cutaneous T cell lymphoma atlas reveals malignant T<sub>H</sub>2 cells supported by a B cell-rich tumor microenvironmentRuoyan Li, Johanna Strobl, Elizabeth F M Poyner, et al.
Nature Immunology|November 18, 2024
Cutaneous T cell lymphoma atlas reveals malignant T<sub>H</sub>2 cells supported by a B cell-rich tumor microenvironmentRuoyan Li, Johanna Strobl, Elizabeth F M Poyner, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Experimental Dermatology|June 16, 2016
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitisSaakshi Khattri, Patrick M Brunner, Sandra Garcet, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
The Journal of Allergy and Clinical Immunology|September 28, 2016
Early-onset pediatric atopic dermatitis is T<sub>H</sub>2 but also T<sub>H</sub>17 polarized in skinHitokazu Esaki, Patrick M Brunner, Yael Renert-Yuval, et al.
Allergo Journal : Interdisziplinare Zeitschrift Fur Allergologie Und Umweltmedizin : Organ Der Deutschen Gesellschaft Fur Allergie- Und Immunitatsforschung|August 16, 2021
Eva Untersmayr, Elisabeth Förster-Waldl, Michael Bonelli, et al.
The Journal of Allergy and Clinical Immunology|August 20, 2018
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumabPatrick M Brunner, Ana B Pavel, Saakshi Khattri, et al.
Allergo Journal International|June 28, 2021
Immunologically relevant aspects of the new COVID-19 vaccines-an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paperEva Untersmayr, Elisabeth Förster-Waldl, Michael Bonelli, et al.
The New England Journal of Medicine|August 20, 2025
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell TherapyAdolfo Aleman, Oliver Van Oekelen, David T Melnekoff, et al.
Nature Immunology|December 2, 2024
Author Correction: Cutaneous T cell lymphoma atlas reveals malignant T<sub>H</sub>2 cells supported by a B cell-rich tumor microenvironmentRuoyan Li, Johanna Strobl, Elizabeth F M Poyner, et al.
Nature Immunology|November 18, 2024
Cutaneous T cell lymphoma atlas reveals malignant T<sub>H</sub>2 cells supported by a B cell-rich tumor microenvironmentRuoyan Li, Johanna Strobl, Elizabeth F M Poyner, et al.
Pageof 9